Search
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic
Etripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational) to sinus rhythm in adults. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigationalLanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.
Categories: Drugs Used in Hereditary AngioedemaClesrovimab
go.drugbank.com/drugs/DB18877Approved[A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Categories: Receptors, Interleukin-1 Type ISynonyms: IL-1 TRAP, IL-1-TRAPCarprofen
go.drugbank.com/drugs/DB00821ApprovedVet approvedWithdrawnIt is no longer marketed for human usage, after being withdrawn on commercial grounds. … Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticAcemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigationalit kept the same side effects. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSProducts: RASLACOF-XOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Categories: Topoisomerase I Inhibitors